Anti-PD-L1 Antibody CDR Engineering for Low-Expression Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing anti-PD-L1 antibodies exhibit insufficient binding affinity to PD-L1 expressed on tumor cells, limiting their therapeutic effectiveness.

Innovation Solution

Development of an antibody or antigen binding fragment with specific CDR sequences (SEQ ID NO: 1-5) that enhance binding affinity to PD-L1 on tumor cells, promoting immune cell activation and anti-cancer function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing anti-PD-L1 antibodies are used, then the therapeutic approach is established, but the binding affinity to PD-L1 is insufficient

Engineering Contradiction:

Improvebinding affinityVSAvoidtherapeutic effectiveness

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by modifying the CDR sequences of the antibody to achieve higher binding affinity. Specifically, the patent provides multiple CDR sequence variants ( SEQ ID NO: 1-5) that differ from existing antibodies, changing the molecular parameters of the antibody to improve its affinity for PD-L1 on tumor cells.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If PD-L1 expression on tumor cells is low, then tumor heterogeneity is maintained, but antibody binding is reduced

Engineering Contradiction:

Improveeffectiveness on low expression tumorsVSAvoidbinding affinity

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by designing antibodies with specifically optimized CDR regions that target particular epitopes on PD-L1. The CDR sequences provided (SEQ ID NO: 1-5) are locally optimized to recognize conformational epitopes that may be accessible even when overall PD-L1 expression is low, allowing effective binding at the tumor cell surface regardless of expression level.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibody or antigen binding fragment effectively blocks the PD-1/PD-L1 interaction, enhancing T cell anti-cancer immunity and tumor killing capabilities, even on tumor cells with low PD-L1 expression.

Implementation Method 1

The antibody or antigen binding fragment effectively blocks the PD-1/PD-L1 interaction

Methodology Applied

Scientific EffectAntibody binding:

Data Source

PatentUS20260078186A1Anti-pdl1 antibody and use thereof

Publication Date: 2026.03.19 HEFEI TG IMMUNOPHARMA CO LTD

AI summary

The present disclosure relates to the field of biomedicine, and more particularly, to an anti-PD-L1 antibody or antigen binding fragment and use thereof. The anti-PD-L1 antibody or antigen binding fragment according to the present disclosure includes a CDR selected from at least one of the following sequences or amino acid sequences having at least 80% identity thereto: heavy chain variable region CDR sequences: SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; or light chain variable region CDR sequences: SEQ ID NO: 4, WAS, or SEQ ID NO: 5. The antibody has a high binding affinity to PD-L1, and the present disclosure also provides a CD3 and PD-L1 bispecific antibody that has a stronger binding to tumor cells and promotes T cells to exert anti-cancer function.